KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

TherapeuticsMD (TXMD) EBT Margin (2016 - 2025)

TherapeuticsMD (TXMD) has disclosed EBT Margin for 16 consecutive years, with 6.38% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBT Margin rose 11003.0% year-over-year to 6.38%, compared with a TTM value of 0.36% through Sep 2025, up 25161.0%, and an annual FY2024 reading of 133.05%, up 46157.0% over the prior year.
  • EBT Margin was 6.38% for Q3 2025 at TherapeuticsMD, down from 57.25% in the prior quarter.
  • Across five years, EBT Margin topped out at 70.67% in Q4 2022 and bottomed at 4273.85% in Q2 2022.
  • Average EBT Margin over 5 years is 865.62%, with a median of 198.24% recorded in 2021.
  • The sharpest move saw EBT Margin tumbled -408842bps in 2022, then soared 372145bps in 2023.
  • Year by year, EBT Margin stood at 65.39% in 2021, then grew by 8bps to 70.67% in 2022, then plummeted by -547bps to 315.54% in 2023, then surged by 104bps to 12.44% in 2024, then crashed by -49bps to 6.38% in 2025.
  • Business Quant data shows EBT Margin for TXMD at 6.38% in Q3 2025, 57.25% in Q2 2025, and 169.97% in Q1 2025.